Table 5.
Summary of binding ADA results
| Visit |
Subjects with binding ADA‐positive results n/N (%) |
||
|---|---|---|---|
|
ABP 959 (N = 71) |
Eculizumab US (N = 72) |
Eculizumab EU N = 74) |
|
| Day 1 (predose) | 4/71 (5.6) | 2/72 (2.8) | 1/74 (1.4) |
| Day 11 | 5/67 (7.5) | 4/64 (6.3) | 6/67 (9.0) |
| Day 29 | 1/67 (1.5) | 2/69 (2.9) | 0/70 (0.0) |
| Day 57 (EOS/ET) | 1/70 (1.4) | 2/68 (2.9) | 1/73 (1.4) |
| Positive at any time during the study | 7/71 (9.9) | 5/72 (6.9) | 7/74 (9.5) |
n = number of subjects with binding ADA‐positive results; N = number of subjects with binding ADA results.
Abbreviations: ADA, anti‐drug antibodies; EOS, end of study; ET, end of treatment.